## patent claims

1. Composition comprising one or more active ingredients and, optionally, one or more nutritional substances, solid, liquid and/or semiliquid excipients or auxiliaries, characterized in that the active ingredients consist of

- a) a <u>component A</u> consisting of one or more compounds selected from methyl and methylene donors,
- b) a component B consisting of one or more methyl transporters, and
- c) a component C consisting of one or more bioflavonoids.
- 2. Composition according to claim 1, characterized in that <u>component A</u> consists of one or more compounds selected from betaine, dimethylglycine, sarcosine and serine or their physiologically acceptable salts.

Composition according to one of claims 1 or 2, characterized in that component B consists of one or more compounds selected from dihydrofolic acid, tetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10-methylenetetrahydrofolic acid, 5,10-methenyltetrahydrofolic acid or their physiologically acceptable salts.

4. Composition according to claim 3, characterized in that component B consists of L-5-methyltetrahydrofolic acid or a physiologically acceptable salt thereof.

5 3 10

15


20

OGBUITES OFFISCE

CA ESI.

30





25

30

35

Composition according to one of claims 1 to 4, characterized in that component C consists of one or more compounds selected from mono-, di- or triglycoside bioflavonoids containing the aglycone quercetin.

Composition according to claim 5, characterized in that <u>component C</u> consists of one or more compounds selected from isoquercetin, quercitrin, isoquercitrin, quercimeritrin, spiraeosid, rutin, and hyperin.

Composition according to one of claims 1 to 6 for the treatment and prevention of transmethy ation disorders.

Composition according to one of claims 1 to 6 for the treatment and prevention of cardiovascular diseases.

9. Composition according to one of claims 1 to 6 for the treatment and prevention of atherogenic and/or thrombogenic diseases.

10. Composition according to one of claims 1 to 6 for the treatment and prevention of diseases associated with hyperhomocysteinemia.

11. Composition according to one of claims 1 to 6 for the treatment and prevention of premature occlusive arterial disease, severe vascular disease in infancy and childhood, progressive arterial stenosis, intermittent claudication, renovascular hypertension, ischemic cerebrovascular disease, premature retinal artery and retinal vein occlusion, cerebral occlusive arterial disease, occlusive peripheral arterial disease, premature death due to thromboembolic disease and/or ischemic heart disease.

12. Use of one or more compounds selected from methyl and methylene donors, one or more methyl transporters, and one or more bioflavonoids in the proparation of a composition for the treatment of transmethylation disorders.

10 22

15

5

20

25

30

35